LDN193189 (GMP)

MedChemExpress

Cat. No.:	HY-12071G	N N
CAS No.:	1062368-24-4	
Molecular Formula:	$C_{25}H_{22}N_{6}$	N
Molecular Weight:	406.48	N-N
Target:	TGF-β Receptor	
Pathway:	TGF-beta/Smad	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	Ň N NH

BIOLOGICAL ACTIV	
DIOLOGICAL ACTIV	
Description	LDN193189 (DM-3189) (GMP) is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 is selective BMP type I receptor inhibitor ^{[1][2]} .
In Vitro	LDN193189 (GMP) (250 nM; 0-7 d) induces human pluripotent stem cells (hPSC) directly differentiates into midbrain dopamine neurons (mDA) ^[1] . LDN193189 (GMP) (200 nM) induces the generation of glucose-responsive β cells from hPSCs in vitro ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Eur Respir J. 2021 Dec 2;2100327.
- Mol Cell. 2022 Jun 3;S1097-2765(22)00480-4.
- Biomaterials. 2020 May;240:119849.
- EMBO Rep. 2023 Jul 26;e56454.
- Stem Cell Res Ther. 2023 Jan 5;14(1):1.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Kim TW, et al. Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. Cell Stem Cell. 2021 Feb 4;28(2):343-355.e5.

[2]. Pagliuca FW, et al. Generation of functional human pancreatic β cells in vitro. Cell. 2014 Oct 9;159(2):428-39.

Product Data Sheet

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA